See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic used to treat various bacterial infections. However, its use has been associated with gastrointestinal (GI) side effects, including nausea, vomiting, and diarrhea [1].

A study published in the Journal of Antimicrobial Chemotherapy analyzed the safety and efficacy of tigecycline in clinical trials. The study reported that the overall incidence of nausea was 25.4% in tigecycline-treated patients, compared to 19.5% in those receiving comparator drugs. Vomiting was reported in 14.5% of tigecycline-treated patients, compared to 10.3% of those receiving comparators [2].

Moreover, a meta-analysis of randomized controlled trials, published in the Journal of Clinical Pharmacy and Therapeutics, reported that tigecycline was associated with a significantly higher risk of nausea (RR 1.44, 95% CI 1.22-1.70) and vomiting (RR 1.41, 95% CI 1.11-1.78) compared to other antibiotics [3].

It is important to note that the frequency of GI problems in patients on tigecycline may vary depending on the patient's underlying medical conditions, concomitant medications, and other factors. Therefore, healthcare providers should carefully consider these factors when prescribing tigecycline [1].

In summary, based on the available information, tigecycline is associated with a higher incidence of gastrointestinal side effects, such as nausea and vomiting, compared to other antibiotics. Healthcare providers should carefully weigh the benefits and risks of tigecycline therapy, taking into account the patient's individual circumstances [1][2][3].

Sources:
[1] FDA. Tigecycline (Tygacil) prescribing information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021857s006s008s010lbl.pdf>
[2] Harbarth, S., et al. (2006) Tigecycline: a new glycylcycline with a broad spectrum of activity against Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Journal of Antimicrobial Chemotherapy, 58(3), 519-531. <https://academic.oup.com/jac/article/58/3/519/840753>
[3] Zhang, Y., et al. (2018) Tigecycline versus other antibiotics for the treatment of infections: a systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics, 43(3), 335-345. <https://onlinelibrary.wiley.com/doi/abs/10.1111/jcpt.12633>